- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.07. | HS market forecast to reach $7.8bn across 7MM by 2034 | ||
| 28.07. | Gilead wins positive European approval opinion for twice-yearly HIV injection | ||
| 28.07. | How linked data can unlock the full potential of healthcare research | ||
| 28.07. | Sanofi's Sarclisa gains EC approval for multiple myeloma treatment | ||
| 28.07. | Hengrui Pharma and GSK link across key therapeutic areas | ||
| 28.07. | Synthetic rescue: Insmed explores a new frontier in genetic therapeutics | ||
| 25.07. | Pharma braces for critical French drug pricing reforms pending CEPS's report | ||
| 25.07. | UK-India $4.8bn FTA poised to benefit medtech and pharma | ||
| 25.07. | CHMP rejects Elevidys in latest setback for Sarepta | ||
| 25.07. | Why the AI hype isn't the whole story: let's focus on the benefits | ||
| 25.07. | The promise and challenges of the Unified Study Definition Model (USDM) | ||
| 25.07. | Pfizer and 3SBio conclude licensing deal for SSGJ-707 | ||
| 25.07. | GSK's Blenrep combos approved for multiple myeloma in EU | ||
| 24.07. | Apnimed sets sights on sleep apnoea pill approval following Phase III win | ||
| 24.07. | Novo Nordisk defeated in Wegovy patent dispute by Viatris | ||
| 24.07. | Kling Bio and Sanofi link for antibodies and epitopes discovery | ||
| 24.07. | How ICH E6 (R3) is changing clinical trials | ||
| 24.07. | Exploring AI-powered cell simulations and the launch of the world's first virtual lab | ||
| 24.07. | Janssen's Darzalex new indication gains EC approval for SMM | ||
| 23.07. | UK enacts law to decentralise manufacture of personalised treatments | ||
| 23.07. | AstraZeneca announces $50bn US investment plans by 2030 | ||
| 23.07. | Sanofi to acquire Vicebio's share capital for $1.15bn upfront | ||
| 22.07. | J&J seeks FDA approval for icotrokinra to treat psoriasis | ||
| 22.07. | Sarepta halts Elevidys shipments following FDA pressure | ||
| 22.07. | Biogen to invest further $2bn in North Carolina's Research Triangle Park |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .